When was Ivantis founded?

Ivantis was founded in 2007 and raised its 1st funding round 1 year after it was founded.

Where is Ivantis located?

Ivantis is headquartered in Irvine, United States. It is registered at Irvine, California.

How many employees does Ivantis have?

As of Dec 31, 2022, Ivantis has 132 employees, reflecting a 76% year-over-year growth in headcount.

Is Ivantis a funded company?

Ivantis is a funded company, having raised a total of $166M across 7 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2008.

When was the latest funding round of Ivantis?

Ivantis' latest funding was a $***** Series C round on Jan 20, 2017, with participation from 2 investors. Its primary sector is Ophthalmology. In United States, the Ophthalmology sector has seen $601M in funding in 2026 to date.

Where does Ivantis rank among its competitors?

Ivantis ranks 5th amongst 30 active competitors, of which 10 are funded. It stands 1st in terms of total funding among its competitors. The most recent competitor to raise funding was Avisi Technologies, which secured $10.7M in Feb, 2026.

Who are the top competitors of Ivantis?

Ivantis' top competitors include Glaukos, Avisi Technologies and Myra Vision. Among them, Avisi Technologies secured the most recent funding round in February, 2026.

Ivantis - 2026 Company Profile, Funding & Competitors

Q: Is Ivantis an acquired company?

Ivantis got acquired by Alcon on Nov 08, 2021.

Ivantis is an acquired company based in Irvine (United States), founded in 2007. It operates as an Innovative microstent solutions for glaucoma management and surgical eye care. Ivantis has raised $166M in funding from investors like New Enterprise Associates, Delphi Ventures and RA Capital Management. The company has 30 active competitors, including 10 funded and 5 that have exited. Its top competitors include companies like Glaukos, Avisi Technologies and Myra Vision.

Company Details

Innovative microstent solutions for glaucoma management and surgical eye care. This company focuses on providing advanced medical devices and solutions for eye health, specifically in the areas of glaucoma and cataract surgery. They offer a range of products including intraocular lenses (IOLs), surgical equipment, procedural eye drops, and disposables. Their flagship product, the Hydrus Microstent, is a minimally invasive glaucoma surgery (MIGS) device designed to reduce intraocular pressure in patients with mild to moderate primary open-angle glaucoma. The company emphasizes evidence-based outcomes and long-term safety in their product development. They also provide resources and training for eye care professionals through platforms like the Alcon Experience Academy. The company supports vision care and surgical customers through digital platforms, offering convenient access to eye health essentials and seamless eCommerce experiences.

Website: ivantisinc.com
Social
Email ID: *****@ivantisinc.com
Registered Address: Irvine, California

Key Metrics

Founded Year

2007

Location

Irvine, United States

Stage

Acquired

Total Funding

$166M in 7 rounds

Latest Funding Round

Series C, Jan 20, 2017, $*****

Investors

New Enterprise Associates & 9 more

Ranked

5^th among 30 active competitors

Employee Count

132 as on Dec 31, 2022

Similar Companies

Glaukos & 35 more

Exit Details

Acquired by Alcon (Nov 08, 2021)

View Ivantis' full profile

Ivantis is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Ivantis, Inc. CIN: 260743432 , United States, Active	Dec 31, 1999	-	132 (As on Dec 31, 2022)	-

Ivantis got acquired by Alcon on Nov 08, 2021 at an acquisition amount of $475M.

Click here to take a look at Ivantis's acquisition in detail

Ivantis has raised a total funding of $166M over 7 rounds. Its first funding round was on 2008. Its latest funding round was a Series C round on Jan 20, 2017 for $*****. 2 investors participated in its latest round. Ivantis has 10 institutional investors.

Here is the list of recent funding rounds of Ivantis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 20, 2017	8887817	Series C	9457862	1937553	2699733	4575280
Oct 14, 2014	4660975	Series C	6941929	5049686	3146511	New Enterprise Associates & 5 more
Jan 13, 2014	4512264	Series B	2080926	6519622	6182602	GBS & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Ivantis's funding rounds and investors

Ivantis' employee count trend

Ivantis has 132 employees as of Dec 22. The total employee count is 76.0% more than what it was in Dec 21. Here is Ivantis's employee count trend over the years:

Uncover Ivantis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ivantis include Glaukos, Avisi Technologies and Myra Vision. Here is the list of Top 10 competitors of Ivantis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Glaukos 2001, Laguna Hills (United States), Public	Developer of implants to treat glaucoma	$118M	Meritech, Domain Associates & 9 others	61/100
2nd	Avisi Technologies 2017, Philadelphia (United States), Series A	Developer of nano-materials	$15.7M	MedVenture Partners, MedTech Innovator & 20 others	61/100
3rd	Myra Vision 2019, Campbell (United States), Series B	Developer of a medical device for the treatment of glaucoma	$42M	Cormorant Asset Management, PA MedTech VC Fund ... & 5 others	60/100
4th	Sanoculis 2012, Kiryat Ono (Israel), Series C	Provider of a surgical device for the treatment of glaucoma	$35M	DNV Capital	50/100
5th	Ivantis 2007, Irvine (United States), Acquired	Innovative microstent solutions for glaucoma management and surgical eye care	$166M	MemorialCare Innovation Fund, RA Capital Management ... & 8 others	49/100
6th	New World Medical 1990, Rancho Cucamonga (United States), Unfunded	Innovating ophthalmic solutions to preserve and enhance vision for humanity	-	-	45/100
7th	Sensimed 2003, Lausanne (Switzerland), Acquired	Provider of a contact lens-based glaucoma monitoring platform	$41.8M	Renaissance, Wellington Partners Venture Capital ... & 7 others	44/100
8th	Transcend Medical 2006, Menlo Park (United States), Acqui-Hired	Glaucoma intervention devices	$122M	Kaiser Permanente Ventures, Investor Growth Capital ... & 10 others	43/100
9th	The Eyetronic Therapy 2007, Kleinmachnow (Germany), Series B	An electrical optic nerve stimulation technology for the treatment of glaucoma	$5.4M	HTGF, Earlybird & 3 others	42/100
10th	InnFocus 2003, Miami (United States), Acquired	Ophthalmology solutions: pharmaceuticals, medical devices, research, development, production, and marketing	$49.4M	Saints Capital, HOYA & 2 others	42/100